Linkage of Fibroblast Growth Factor 23 and Phosphate in Serum: Phosphate and Fibroblast Growth Factor 23 Reduction by Increasing Dose of Sevelamer

Amir Ghorbanihaghjo1, Hassan Argani2, Zahra Golmohamadi1, Nadereh Rashtchizadeh3, Mehran Mesgari Abbasi4, Nasrin Bargahi1, Amir Mansour Vatankhah4, Davoud Sanajou1

1Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz; 2Urology and Nephrology Research Center, Beheshti University of Medical Sciences, Tehran; 3Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz; 4Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Corresponding author
Zahra Golmohamadi
Biotechnology Research Center, Tabriz University of Medical Sciences, Shariati Street, Tabriz 51368, Iran
Tel: +98-41-3336-4038
Fax: +98-41-3336-4038
E-mail: rozag2001@gmail.com

Received: May 15, 2018
Revised: August 8, 2018
Accepted: August 12, 2018

No potential conflict of interest relevant to this article was reported.

Background: High serum phosphate and fibroblast growth factor-23 (FGF-23) levels are well-recognized independent risk factors of mortality and morbidity in patients with chronic kidney diseases (CKDs). Sevelamer, as a phosphate chelating agent, reduces serum phosphate and FGF-23 levels produced by bone osteocytes. This study aimed to determine the best dose at which sevelamer could successfully reduce serum phosphate and FGF-23 levels in rat models of adenine-induced CKD. Methods: CKD was induced using adenine. Healthy and CKD-induced rats were divided into 6 groups as follows: healthy controls; CKD controls; rats treated with 1%, 2%, and 3% sevelamer for CKDs; and healthy rats administered 3% sevelamer. Biochemical factors and serum FGF-23 levels were measured using spectrophotometry and enzyme-linked immunosorbent assay methods. Results: Serum phosphate levels were best decreased in rats receiving 3% sevelamer in their diet (5.91 ± 1.48 mg/dL vs. 8.09 ± 1.70 mg/dL, P < 0.05) compared with the CKD control rats. A dose-dependent decrease in serum FGF-23 levels was observed, and the most significant results were obtained in rats receiving 3% sevelamer compared with the CKD control rats (142.60 ± 83.95 pg/mL vs. 297.15 ± 131.10 pg/mL, P < 0.01). Conclusions: Higher sevelamer doses significantly reduced serum phosphate and FGF-23 levels in adenine-induced CKD rats.

Key Words: Chronic · Phosphates · Renal insufficiency · Sevelamer

INTRODUCTION

Chronic kidney disease (CKD) is a general health problem and considered as an independent risk factor for cardiovascular disease events including vascular calcifications.[1,2]

Fibroblast growth factor-23 (FGF-23) is a hormone produced principally by the bone osteocytes in a feedback response to increased plasma phosphate levels and acts on renal tubular cells to promote the expression of Na\(^+\)-phosphate sym-
porters and to lower the production of active vitamin D3, hence leading to increased urinary phosphate excretion and decreased intestinal phosphate absorption in normal individuals and CKD patients.[3,4]

Prevention of early raise in serum FGF-23 levels could possibly counteract the premature decline in serum active vitamin D3 levels and thus the impending rise in the serum parathyromone levels. As evidenced by some authors, there is a positive correlation between low serum FGF-23 levels and CKD progression, vascular calcification, and mortality.[5,6].

Apart from nontraditional risk factors encountered in CKD patients including vitamin D deficiency and hyperparathyroidism, namely CKD-mineral and bone disorder (CKD-MBD), FGF-23 by itself has been demonstrated to correlate with vascular calcification.[7,8] Furthermore as displayed by recent studies, the incidence of its related complications and, overall mortality rates are all associated with the serum phosphate levels within the upper limits of normal range.[9]

It has been well recognized that high serum phosphate levels contributes to the progression of renal damage and the means to turn serum phosphate levels down have improved kidney functions.[10] Decreased nephron mass and the associated impairment in renal phosphate excretion is a cardinal feature in CKD. Phosphate retention not only leads to secondary hyperparathyroidism but also is partially responsible for the renal failure by increasing the chances of renal calcification.[11]

Growing evidence showed that rising FGF-23 levels in early stages of CKD are partially accountable for maintaining phosphatemia within the normal range.[12]

Although it is mostly assumed that high serum levels of phosphate can directly stimulate FGF-23 secretion, explicit confirming evidence is lacking. Indeed, changes in phosphate of serum did not precede changes in serum FGF-23 levels in phosphate feeding subjects.[7,13-15]

Several phosphate binding agents such as sevelamer hydrochloride are currently available for control of hyperphosphatemia in advanced CKD and in hemodialysis patients. The effects of sevelamer also include actions on oxidative stress, inflammation, lipid profile, endothelial dysfunction, and vascular calcification have been reported.[16]

Recent studies have shown that, sevelamer can diminish serum phosphate and consequently FGF-23 levels with high efficiency, which may contribute to its prevention of CKD progress.[17,18] Additional benefactions effects of sevelamer including its ability to impede vascular calcification and alleviate bone disorders in CKD patients makes it a highly prominent therapeutic candidate.[19]

In the present study we used a rat model of adenine induced renal failure and examined the effects of different doses of sevelamer hydrochloride (1%, 2%, and 3% in diet) on serum levels of phosphate and FGF-23, and at the same time monitored the serum creatinine levels as a marker of kidney function. Our current working hypothesis is that an exponential increment in the serum levels of FGF-23 in CKD is enforced by restoring normal phosphorus homeostasis.

**METHODS**

1. **Ethic statement**

   Ethical approval of the study was obtained from Ethical Board of Tabriz University of medical sciences, Experimental animals laboratory (IR.TBZMED.REC.1395.1084). The application form included a statement guaranteeing strict observance to the animals' rights. Attention to this rule was paid throughout the study.

2. **Animals of study**

   Male Wistar rats weighing 226±31 g were obtained from the Laboratory Animal Center of Faculty of Medicine. Animals were kept in sterilized cages at 24±2°C with 12-hr cycles of light and dark along with free access to water and standard pellet (normal diet, CE-2).

3. **Group design (drug treatment)**

   Renal failure was induced in male rats by feeding 0.75% adenine-containing diet for 4 weeks.[20] After an acclimatization period of 1 week, they were divided into 6 groups. The first group continued to receive the same diet without treatment until the end of the study (Normal group, n=8).

   The groups 2, 3, 4, and 5 were switched to a diet containing 0.75% adenine (Sigma Chemical Co., St. Louis, MO, USA). At the day 28 after the onset of diet containing adenine, tail vein blood samples were collected to measure serum levels of creatinine, and phosphate to verify the induction of CKD.

   Then again induced CKD rats were divided into 4 groups (groups 2-5) that were matched for body weight, serum
phosphate, calcium, and creatinine; and next were given diets with 0% sevelamer (n=10), 1% sevelamer (n=8), 2% sevelamer (n=8), 3% sevelamer (n=8) for 4 weeks. Sevelamer was mixed into normal diet. The rats in group 6 (n=10) were normal animals without receiving adenine but fed 3% sevelamer (Fig. 1). The quantities of feed eaten by each group were recorded each day. At the week 4 after onset of sevelamer, animals were weighed and anesthesia was performed using a single dose of ketamine (100 mg/kg, i.p.). Venous blood was collected and after clotting, samples were centrifuged at 3,000 g for 15 min and the separated serums were kept at -80°C until tested.

4. Determination of serum parameters
Serum creatinine, calcium, and phosphate levels were measured using an automatic serum analyzer (Cobas Mira Plus Chemistry System; Roche Diagnostic Systems, Indianapolis, IN, USA). Calcium × phosphate product, an indicator of metastatic calcification was calculated. Serum FGF-23 levels were measured using an enzyme-linked immunosorbent assay kit (BT, Bioassay Technology laboratory).

5. Statistical analysis
Data were analyzed using SPSS (SPSS Inc., Chicago, IL, USA) and expressed as mean ± standard deviation (SD). An unpaired t-test was used to compare the adenine-control group with the normal-control group. Differences between groups were analyzed using a one-way analysis of variance (ANOVA), and Dunnett’s test. P<0.05 values were considered to be significant. Association between parameters was analyzed using the correlation coefficient analysis.

RESULTS
There were no significant differences in average daily food intake during the study between treatment and CKD control groups. No significant changes in animal weights were seen after switching to diets containing adenine or sevelamer. CKD rats had significantly lower weights as compared to normal ones and this difference dramatized with the progress of study (Table 1).

Serum creatinine and phosphate levels were higher in rats receiving adenine compared with normal controls, while serum calcium levels were nearly the same among those groups. At the end of the study, groups receiving sevelamer demonstrated still higher levels of serum creatinine, nonetheless a slight albeit statistically insignificant decrease in their levels was noted (Table 2).

| Parameter | Time | Normal | CKD | 1% Sev | 2% Sev | 3% Sev | Normal (3% Sev) |
|-----------|------|--------|-----|--------|--------|--------|----------------|
| BW (g)    | 0 week | 219.50±56.10 | 231.20±41.00 | 214.20±33.00 | 230.30±39.00 | 221.60±11.00 | 221.60±11.00 |
|           | 4 weeks  | 260.20±24.40 | 178.70±21.60<sup>a</sup> | 169.70±25.00<sup>a</sup> | 175.70±39.00<sup>a</sup> | 175.70±18.00<sup>a</sup> | 219.30±14.50<sup>a</sup> |
|           | 8 weeks  | 291.80±26.80 | 225.60±30.00 | 221.70±22.70 | 239.80±39.50 | 233.00±19.90 | 195.60±13.05 |

The data is presented as mean ± standard deviation.
<sup>a</sup>P<0.001 vs. normal control group.

BW, body weight; CKD, chronic kidney disease; Sev, sevelamer hydrochloride.

Fig. 1. The experimental design. From 0 week to 4 weeks, adenine diet was administered for the four groups (CKD control group, 1%, 2%, or 3% sevelamer administered groups). At day 28, adenine diet was stopped and after that normal diet was used. At day 28 the administration of sevelamer was started and sevelamer was administered at 1%, 2%, or 3% mixture diet for 4 weeks. Next group included normal rats, fed 3% sevelamer. CKD, chronic kidney disease.
As expected, CKD rats had significantly higher levels of phosphate, FGF-23, and calcium×phosphate product. Sevelamer dose-dependently decreased serum levels of phosphate; though as noted in Table 2, statistically relevant reduction only was seen at doses of 2% and 3% sevelamer in diet. Serum calcium levels were nearly constant throughout the study and no significant change was observed before and after sevelamer treatment in CKD groups (Table 2). Sevelamer treatment had significant effect on calcium×phosphate product in 3% sevelamer treat.

As shown in Table 3, CKD group had high levels of FGF-23 and 1%, 2%, and 3% sevelamer treatment could successfully decrease its levels in a dose-dependent manner, worthy to say that the most significant results obtained in 3% dose of sevelamer compared to CKD group (142.60±83.95 pg/mL vs. 297.15±131.10 pg/mL, P<0.01). We found that FGF-23 is positively correlated with serum phosphate (r=0.43, P=0.01) and also were observed a significant positive correlation among FGF-23 and the Ca×P product, (r=0.36, P=0.04) (Fig. 2, 3). calcium×phosphate product

### Table 2. Changes of serum biochemical parameters before and after sevelamer administration in all study groups

| Parameter | Time | Normal | CKD | 1% Sev | 2% Sev | 3% Sev | Normal (3% Sev) |
|-----------|------|--------|-----|--------|--------|--------|-----------------|
| Cr (mg/dL) | 4 weeks | 0.41±0.10 | 2.30±0.96 | 2.23±0.82 | 2.65±0.82 | 2.28±0.78 | 0.46±0.11 |
| P (mg/dL) | 4 weeks | 4.87±0.46 | 8.10±2.53 | 8.07±2.43 | 8.17±2.70 | 7.98±1.70 | 3.94±0.54 |
| Ca (mg/dL) | 4 weeks | 9.35±0.43 | 9.47±0.87 | 9.55±0.99 | 8.93±1.58 | 9.26±0.65 | 9.78±0.63 |
| Ca×P (mg$^2$/dL$^2$) | 4 weeks | 45.49±4.13 | 76.72±25.56 | 77.75±27.20 | 72.45±35.44 | 73.52±14.52 | 39.20±6.22 |

The data is presented as mean±standard deviation.

### Table 3. Effect of sevelamer on serum levels of fibroblast growth factor 23 in all study groups in end of study

| Groups | Normal | Control | 1% Sev | 2% Sev | 3% Sev | Normal (3% Sev) |
|--------|--------|---------|--------|--------|--------|-----------------|
| FGF23 (pg/mL) | 96.69±26.71 | 297.15±131.10 | 185.01±84.88 | 177.59±77.50 | 142.60±83.95 | 88.70±22.25 |

The data is presented as mean±standard deviation.

---

**Fig. 2.** Correlation between serum FGF-23 and phosphate in chronic kidney disease and sevelamer treated groups. FGF-23, fibroblast growth factor-23.

**Fig. 3.** Relation between FGF-23 and Ca×P product in chronic kidney disease and sevelamer treat groups. FGF-23, fibroblast growth factor-23; Ca, calcium; P, phosphorus.
is a parameter to evaluate the risk of extra skeletal calcification in CKD patients. Serum FGF-23 is not correlated with serum calcium.

**DISCUSSION**

The present study emphasize many previous studies that showed rising serum FGF-23 levels in early stages of CKD are partially responsible for maintaining phosphate-mia. Sevelamer successfully reduced serum levels of phosphate at doses of 2% and 3% in diet. Sevelamer dose-dependently decreased serum FGF-23 levels in rat models of renal failure. Sevelamer could not significantly reduce the serum levels of creatinine after 4 weeks of administration.

In our study serum levels of creatinine were decreased with sevelamer treatment in CKD rats but this reduction was not statistically significant in agreement with the study conducted by Nagano et al.[21] in 2006. This phenomenon could possibly be attributed to the short duration of our study. Though as the treatment duration in the study conducted by Nagano et al.[22] lasted for 2 month, it could be inferred that sevelamer alone is not sufficient for significant renal functioning improvement. Nevertheless one study done in 2003 with two 1% and 3% doses of sevelamer with a treatment duration of 58 days has reported that statistically significant reduction in serum BUN and creatinine levels were achieved in induced CKD models.

The results of present study showed that, serum levels of phosphate were dose-dependently decreased with 1%, 2%, and 3% sevelamer treatment; however, statistically significant reduction was not seen in 1% sevelamer group. As opposed to our result, Nagano et al.[21,22] reported that 1% sevelamer successfully reduced serum phosphate levels to the extent that prevented hyperphosphatemia in the both 2003 and 2006 studies. The extent of impairment in kidney function also was higher in our study as indicated by higher levels of creatinine compared with mentioned studies.

Treatment with 3% sevelamer led to reduce the serum phosphate levels with no changes in serum calcium levels that was accompanied by a decline in calcium × phosphate product, an indicator of metastatic calcification; the finding that emphasizes the benefits of 3% sevelamer over other to 1% and 2% doses. Significant positive correlation of FGF-23 also with the serum phosphorus and calcium × phosphate product were observed.

In accordance with the results obtained in several previously published papers,[18,21-23] raising in serum FGF-23 levels resulting from adenine-induced CKD, were significantly reduced after sevelamer-induced treatment in our study in a dose dependent manner; albeit FGF-23-lowering effect of sevelamer was only noted in CKD groups, and normal animals receiving sevelamer demonstrated reduced serum phosphate levels, yet had nearly normal serum FGF-23.

The explanation could be the one as follows: FGF-23 down regulates the expression of 1-α-hydroxylase in the kidney, leading to reduced levels of circulating active vitamin D in the blood, the outcome of which is reduced intestinal absorption of phosphate.[24] It seems that normal homeostasis of phosphate and FGF-23 in healthy animals is responsible for the constant levels of FGF-23.

Contradictory results has been obtained regarding the relationship between phosphate and FGF-23 levels in previous studies; for instance rats undergone 5/6 nephrectomy displayed high blood levels of FGF-23 despite receiving a phosphorus-free diet, while the expression of FGF-23 did elevated in cultured osteoblasts in response to incubation with accumulative loads of phosphorus.[25] These findings may propose the existence of phosphate independent regulation mechanism for FGF-23 production. Aside from studies mentioned, CKD patients treated with sevelamer carbonate did not show any significant variations in plasma FGF-23 levels while a significant decrease in serum phosphate levels was noted in these patients.[26]

In support of proceeding results, study conducted by Yilmaz et al.[27] illustrated that the variations seen in serum FGF-23 levels induced by phosphate chelators are accompanied by simultaneous alterations in flow-mediated vasodilatation independently of phosphate levels in serum, and therefore it is possible that an advanced hyperphosphatemia in conjunction with high levels of FGF-23, may not be mitigated by phosphate reduction alone in CKD patients.[26]

Ketteler and Biggar [28] prospective randomized trial in moderate CKD patients with the upper normal range phosphate levels showed only moderate reductions in serum phosphate levels and no effects on serum FGF-23, but increased vascular calcification progression with active treatment versus placebo.

Another even more conflicting study published in 2010
by Oliveira et al.[3] showed that sevelamer is able to de-
cline serum FGF-23 without affecting serum phosphate
levels in normo-phosphatemic pre-dialysis CKD patients.
Nevertheless it is worthy to note that these results chal-
lenge the phosphate-binding nature of sevelamer and as
evidenced in our study, sevelamer when administered at
doses of 2% and 3% significantly reduced serum phos-
phate levels, though in normal rats no meaningful effect
was observed on serum FGF-23 levels. Bearing in mind all
the results presented earlier, it appears necessary to appre-
hend fully the underlying mechanisms related to serum
phosphate and FGF-23 regulation in CKD patients.[29]

Yokota et al.[29] came to the conclusion by computa-
tional simulations that high FGF-23 levels in CKD patients
is not a cause rather is an outcome of an ineffective FGF-
23-mediated phosphorus removal and thereby rejected the
assumption that the elevated level of FGF-23 in serum in
CKD is a direct cause of hyperphosphatemia. In Yokota
mathematical model use of FGF-23 antibody in CKD did
not result in removing phosphorous burden and herein do
not backing the notion that the rising serum levels of FGF-
23 in CKD is a direct cause of hyperphosphotemia.

The accurate mechanism of FGF-23 regulation in CKD is
not known, and further basic and clinical studies are nec-
essary. It is needful to figure out the mechanism in CKD in
which the level of FGF-23 is high without effectively regu-
lating of phosphorus.

CONCLUSIONS

In conclusion, 3% sevelamer significantly reduced serum
levels of phosphate, calcium × phosphate product and
FGF-23 and is recommended over the 1% and 2% doses in
diet. Even at this higher dose of 3% Sevelamer, no signifi-
cant reduction in serum levels of creatinine, the marker of
kidney function, was noted.

ACKNOWLEDGMENTS

This work is funded by a PhD grant of the Biotechnology
Research Center, Tabriz University of Medical Sciences.

REFERENCES

1. Denker M, Boyle S, Anderson AH, et al. Chronic renal in-
sufficiency cohort study (CRIC): overview and summary of
selected findings. Clin J Am Soc Nephrol 2015;10:2073-83.
2. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney
disease as a risk factor for cardiovascular disease and all-
cause mortality: a pooled analysis of community-based
studies. J Am Soc Nephrol 2004;15:1307-15.
3. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of
PTH and FGF23 in normophosphatemic CKD patients: a
new target in CKD-MBD therapy? Clin J Am Soc Nephrol
2010;5:286-91.
4. Munoz Mendoza J, Isakova T, Ricardo AC, et al. Fibroblast
growth factor 23 and Inflammation in CKD. Clin J Am Soc
Nephrol 2012;7:1155-62.
5. Gutiérrrez OM, Mannstadt M, Isakova T, et al. Fibroblast
growth factor 23 and mortality among patients undergo-
ing hemodialysis. N Engl J Med 2008;359:584-92.
6. Wesseling-Perry K. FGF23: is it ready for prime time? Clin
Chem 2011;57:1476-7.
7. Burnett SM, Gunawardene SC, Bringhurst FR, et al. Regu-
lation of C-terminal and intact FGF-23 by dietary phosphate
in men and women. J Bone Miner Res 2006;21:1187-96.
8. Muñoz-García B, Martín-Ventura JL, Martínez E, et al. Fn14
is upregulated in cytokine-stimulated vascular smooth
muscle cells and is expressed in human carotid atheroscle-
rotic plaques: modulation by atorvastatin. Stroke 2006;37:
2044-53.
9. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23
and risks of mortality and end-stage renal disease in pa-
tients with chronic kidney disease. JAMA 2011;305:2432-9.
10. Gutiérrrez OM, Wolf M, Taylor EN. Fibroblast growth factor
23, cardiovascular disease risk factors, and phosphorus in-
take in the health professionals follow-up study. Clin J Am
Soc Nephrol 2011;6:2871-8.
11. Cozzolino M, Dusso AS, Liapis H, et al. The effects of sevel-
amer hydrochloride and calcium carbonate on kidney cal-
cification in uremic rats. J Am Soc Nephrol 2002;13:2299-
308.
12. Ketteler M, Petermann AT. Phosphate and FGF23 in early
CKD: on how to tackle an invisible foe. Nephrol Dial Trans-
plant 2011;26:2432-2.
13. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23
relationship to dietary phosphate and renal phosphate
handling in healthy young men. J Clin Endocrinol Metab
2005;90:1519-24.
14. Antoniucci DM, Yamashita T, Portale AA. Dietary phospho-
rus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006;91:3144-9.

15. Ito N, Fukumoto S, Takeuchi Y, et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 2007;25:419-22.

16. Rodríguez-Osorio L, Zambrano DP, Gracia-Iguacel C, et al. Use of sevelamer in chronic kidney disease: beyond phosphorus control. Nefrologia 2015;35:207-17.

17. Koiwa F, Kazama JJ, Tokumoto A, et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005;9:336-9.

18. Nagano N, Miyata S, Abe M, et al. Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease. Clin Calcium 2005;15 Suppl 1:35-9; discussion 9-40.

19. Spaia S. Phosphate binders: sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia 2011;15:22-6.

20. Tamagaki K, Yuan Q, Ohkawa H, et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant 2006;21:651-9.

21. Nagano N, Miyata S, Abe M, et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006;69:531-7.

22. Nagano N, Miyata S, Obana S, et al. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2003;18:2014-23.

23. Cancela AL, Oliveira RB, Graciolli FG, et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 2011;117:c74-82.

24. Bansal S. New insights into regulation of FGF23 in chronic kidney disease and its role in cardiovascular disease. SM J Cardiolog and Cardiovasc Disord 2015;1:1003.

25. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15.

26. Spatz C, Roe K, Lehman E, et al. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Nephron Clin Pract 2013;123:61-6.

27. Yilmaz MI, Sonmez A, Saglam M, et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis 2012;59:177-85.

28. Ketteler M, Biggar PH. Use of phosphate binders in chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22:413-20.

29. Yokota H, Pires A, Raposo JF, et al. Model-based analysis of FGF23 regulation in chronic kidney disease. Gene Regul Syst Bio 2010;4:53-60.
